Clinical trials: Hepatitis
Hepatitis B, Chronic
Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir
The presence of persistent inadequate or suboptimal virologic response is a strong risk factor for viral resistance and breakthrough and also for disease progression of chronic hepatitis B, and thus, a change in therapy is…
- Trial name
- CAESAR (NCT01023217)
- Testing
- Adefovir, Entecavir, Lamivudine
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Asan Medical Center
Hepatitis C
Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy
Hepatitis C is the leading cause of chronic liver disease in industrialized countries, and is the most common indication for liver transplantation.
- Trial name
- NCT01045278
- Testing
- Pegylated interferon-alfa-2b and ribavirin
- Where
- Sweden
- Volunteers
- 277 people
- Sponsor
- Region Skane
Hepatitis C
Pilot Trial of Directly Observed Anti HCV Therapy & Contingency Management in a Population on Opiate Substitute Therapy
DOT-C is a cluster randomised trial of a pharmacist-led, directly observed anti HCV therapy pathway versus the conventional care pathway within community pharmacies.
- Trial name
- DOT-C (NCT03483818)
- Testing
- Assessment & Treatment of HCV infection with oral antivirals
- Where
- United Kingdom
- Volunteers
- 152 people
- Sponsor
- NHS Tayside
Chronic Hepatitis B
Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg
Background: The HBsAg clearance rate in interferon-treated responders is significantly higher than that in lamivudine-treated responders, implying immune control is the key to HBsAg clearance.
- Trial name
- NCT01817725
- Testing
- HBV vaccine (Engerix B)
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatitis B
Acceptability of Hepatitis B Vaccination in General Practitioners and Paediatricians
The present study is conducted in order to assess the acceptability of Hepatitis B vaccination in French general practitioners and peadiatricians before and after reimbursement of the paediatric vaccine InfanrixHexa.
- Trial name
- PRALINE (NCT01777074)
- Testing
- Data collection
- Where
- 402 sites in France
- Volunteers
- 474 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HBV, Chronic Hepatitis b
A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
This is a multicenter, prospective, real-world study. The study plans to include a total of 2000 patients who meet the inclusion and exclusion criteria, consisting of 1600 treatment-naive patients and 400 treatment-experienced…
- Trial name
- NCT06926647
- Testing
- Nucleos(t)ide Analogues, Interferon alfa, NAs combined with IFNα
- Where
- 85 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Beijing 302 Hospital
Hepatitis C, Chronic Hepatitis
Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
The purpose of this study is to evaluate daclatasvir in combination with sofosbuvir given to children with chronic hepatitis C infection
- Trial name
- NCT03487848
- Testing
- Daclatasvir, Sofosbuvir
- Where
- 2 sites in Australia, Spain
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis E
A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults
Hepatitis E is characteristic by sporadic and local epidemic around the world, and mainly infects adults aged 15 to 40 years old, resulting in the infection rate ranged from 1% to 15%.
- Trial name
- NCT02603055
- Testing
- 30μg/0.5ml Hepatitis E vaccine, 30μg/0.5ml Recombinant Hepatitis E vaccine
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Hepatitis-Associated Aplastic Anemia
Collection of Biological Samples From Patients With Hepatitis-Associated Aplastic Anemia
This study will collect samples of blood, stool, bone marrow, or other tissues from patients with hepatitis-associated aplastic anemia to investigate a possible association between exposure to viruses and the development of…
- Trial name
- NCT00050115
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hepatitis C, Chronic, Children, Only
Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years
Recently the era of direct-acting antiviral drugs for hepatitis C treatment has changed the world map of HCV. Results in adults are promising. FDA approved only two drugs in the pediatric age group 12 to 17 years.
- Trial name
- NCT03764345
- Testing
- Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- National Liver Institute, Egypt
Hepatitis B
Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control
The purpose of the present study is to evaluate the immunogenicity and safety of three consecutive production lots of the novel adjuvanted HBV vaccine.
- Trial name
- NCT00697866
- Testing
- HBV-MPL vaccine 208129, Engerix™-B
- Volunteers
- 951 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic, Hepatitis C
Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)
This is a post-marketing surveillance of patients with chronic hepatitis C treated with PegIntron and Rebetol combination therapy in clinical practice in Japan.
- Trial name
- NCT00724295
- Testing
- peginterferon alfa-2b, ribavirin
- Volunteers
- 1,077 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV, Hepatitis C
Effects of Motivational Interviewing on Risky Injecting Practices Among Injecting Drug Users (IDUs)
The purpose of this study is to evaluate the effects of a brief motivational intervention in reducing risky injection practices among injecting drug users (IDUs).
- Trial name
- NCT00794391
- Testing
- Motivational interviewing, Educational intervention
- Where
- Canada
- Volunteers
- 219 people
- Sponsor
- Université de Sherbrooke
Hepatitis
Collections of Blood and Stool Samples in Patients With Acute Hepatitis
Hepatitis is an inflammation of the liver. Hepatitis can be caused by an infection with a virus, but poisonous (toxic) substances can also cause it.
- Trial name
- NCT00001879
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Hepatitis B
Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B
Currently, seven medications are approved for the treatment of hepatitis B: two formulations of interferon and five nucleons(t)ide analogues.
- Trial name
- NCT01906580
- Testing
- Peg-IFNα-2a, Entecavir
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Beijing 302 Hospital
Hepatitis C
Link Hepatitis C Notifications to Treatment in Tasmania
This project will utilise the notification process as a point of intervention to work with primary practitioners (GP) by contacting them directly when a notification of hepatitis C exposure is received by the Tasmanian department…
- Trial name
- NCT04510246
- Testing
- Enhanced case management
- Where
- Australia
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Hepatitis A Virus Infection
A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)
This study will demonstrate the immunogenicity and evaluate the safety/tolerability of the vaccine in Chinese children between 12 and 23 months of age.
- Trial name
- NCT00835380
- Testing
- Hepatitis A Vaccine, Purified Inactivated (VAQTA™)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B, Chronic
Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)
The purpose of this study is to confirm efficacy and safety when administering lamivudine tablet alone in subjects with hepatitis B virus-induced liver cirrhosis.
- Trial name
- NCT01376154
- Testing
- Lamivudine
- Volunteers
- 342 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Hemophilia
Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
Hemophilic patients are a known high risk groups for acquiring the hepatitis C. The surveillance data from Ministry Of Health in IR.Iran had shown that 60% of them are infected with HCV infection.
- Trial name
- NCT00707772
- Testing
- PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
- Where
- Iran
- Volunteers
- 400 people
- Sponsor
- Baqiyatallah Medical Sciences University
Hepatitis C Virus
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.
- Trial name
- UNITY 4 (NCT02170727)
- Testing
- DCV/ASV/BMS-791325
- Where
- 20 sites in Russia, South Korea and 1 more
- Volunteers
- 199 people
- Sponsor
- Bristol-Myers Squibb